Top FDA official says would resign if agency rubber-stamps an unproven Covid-19 vaccine
Skip to main content
  • Home
  • Economy
    • Aviation
    • Bazaar
    • Budget
    • Industry
    • NBR
    • RMG
    • Corporates
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Features
    • Book Review
    • Brands
    • Earth
    • Explorer
    • Fact Check
    • Family
    • Food
    • Game Reviews
    • Good Practices
    • Habitat
    • Humour
    • In Focus
    • Luxury
    • Mode
    • Panorama
    • Pursuit
    • Wealth
    • Wellbeing
    • Wheels
  • Epaper
  • More
    • Subscribe
    • Videos
    • Thoughts
    • Splash
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • COVID-19
    • Games
    • Long Read
    • Interviews
    • Offbeat
    • Podcast
    • Quiz
    • Tech
    • Trial By Trivia
    • Magazine
  • বাংলা
The Business Standard

Tuesday
February 07, 2023

Sign In
Subscribe
  • Home
  • Economy
    • Aviation
    • Bazaar
    • Budget
    • Industry
    • NBR
    • RMG
    • Corporates
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Features
    • Book Review
    • Brands
    • Earth
    • Explorer
    • Fact Check
    • Family
    • Food
    • Game Reviews
    • Good Practices
    • Habitat
    • Humour
    • In Focus
    • Luxury
    • Mode
    • Panorama
    • Pursuit
    • Wealth
    • Wellbeing
    • Wheels
  • Epaper
  • More
    • Subscribe
    • Videos
    • Thoughts
    • Splash
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • COVID-19
    • Games
    • Long Read
    • Interviews
    • Offbeat
    • Podcast
    • Quiz
    • Tech
    • Trial By Trivia
    • Magazine
  • বাংলা
TUESDAY, FEBRUARY 07, 2023
Top FDA official says would resign if agency rubber-stamps an unproven Covid-19 vaccine

World+Biz

Reuters
22 August, 2020, 10:50 am
Last modified: 22 August, 2020, 10:57 am

Related News

  • US FDA approves Mirati's lung cancer drug
  • California lab-grown meat start-up gets first green light
  • US FDA authorizes Eli Lilly's Covid-19 antibody drug
  • Pfizer asks FDA to allow Covid-19 vaccine for kids under 5
  • FDA expands use of remdesivir to patients with high risk of hospitalization

Top FDA official says would resign if agency rubber-stamps an unproven Covid-19 vaccine

Reuters
22 August, 2020, 10:50 am
Last modified: 22 August, 2020, 10:57 am
Top FDA official says would resign if agency rubber-stamps an unproven Covid-19 vaccine

A top US health regulator who will help decide the fate of a coronavirus vaccine has vowed to resign if the Trump administration approves a vaccine before it is shown to be safe and effective, Reuters has learned.

Peter Marks, director of the Food and Drug Administration's Center for Biologics Evaluation and Research, made the statement in response to concerns raised on a conference call late last week of government officials, pharmaceutical executives and academics who serve on a vaccine working group organized by the National Institutes of Health, according to three sources familiar with the matter.

When contacted by Reuters, Marks confirmed the account.

Scientists, public health officials and lawmakers are worried that the Trump administration will pressure the FDA to authorize a Covid-19 vaccine in advance of the November presidential election, even if data from clinical trials do not support its widespread use.

Marks told Reuters he has not faced any political pressure and that the FDA would be guided by science alone. Should that change, "I could not stand by and see something that was unsafe or ineffective that was being put through," Marks said.

"You have to decide where your red line is, and that's my red line," he said. "I would feel obligated (to resign) because in doing so, I would indicate to the American public that there's something wrong."

He added that he would equally object if someone sought political gain by holding up approval of a vaccine that was shown to work, and that was safe.

Michael Caputo, assistant secretary for public affairs at the Department of Health and Human Services, which oversees FDA and NIH, said the government aims to identify a safe and effective vaccine by January 2021.

Speculation about the FDA approving a vaccine under political pressure "only undermines confidence in the public health system," Caputo said in a statement. "I've never met one FDA regulator who wouldn't resign over improper pressure, and that's how America knows their seal of approval is the gold standard."

The FDA declined to comment on the meeting.

President Donald Trump's approval ratings have fallen sharply in the wake of a pandemic that has killed more than 173,000 Americans and infected over 5.5 million. The race to produce a vaccine has become the centerpiece of his administration's response.

Earlier this month, Trump said a vaccine was possible before the Nov. 3 vote.

In a statement on Thursday, FDA Commissioner Stephen Hahn said that under Marks' leadership, the agency's scientists are monitoring the Covid-19 vaccine trials, "the data from which will be the deciding factor for any FDA approval."

Anthony Fauci, the nation's leading infectious disease expert, has also said publicly that political considerations will not influence any decision on a coronavirus vaccine.

October Surprise?

Large-scale clinical trials of the leading vaccine candidates from Moderna Inc (MRNA.O), Pfizer Inc (PFE.N) and AstraZeneca Plc (AZN.L) were launched in recent weeks.

The FDA has scheduled a meeting of its advisory committee of outside experts on coronavirus vaccines on Oct. 22.

Marks said the trials were enrolling volunteers "reasonably well" and that it was "possible" data could be available to interpret as early as October. If not, the committee could still discuss broader regulatory issues regarding a vaccine, he said.

On the NIH call with members of its vaccine working group on Aug. 14, some participants asked whether it was realistic to expect sufficient safety and efficacy data from those trials before the election, the sources familiar with the matter said.

The discussion then turned to concerns about a so-called October surprise announcement, in which the Trump administration rushes to unveil a vaccine candidate, the sources said.

At that point, they said, Marks told participants on the call that if the FDA were pressured to approve a vaccine without enough evidence of it being safe and effective, he would resign.

"It was pretty dramatic," one of the sources said. "It was a bold statement."

Emergency Use

The U.S. government has invested nearly $11 billion to help develop and manufacture more than half a dozen coronavirus vaccine candidates. Fauci has said the project, dubbed Operation Warp Speed, could identify a successful vaccine by January 2021 and provide tens of millions of doses early in the year.

Marks, a hematologist, has worked at FDA since 2012 and oversees a division responsible for regulating cutting-edge biotech treatments, vaccines and gene therapies.

The agency's commissioner Hahn, a political appointee, typically has the power to issue an emergency authorization for a vaccine, expediting the traditional approval process in situations like the current pandemic.

Marks is the top FDA scientist involved in the process, charged with making a recommendation on any potential vaccine candidate. The Health and Human Services secretary could also overrule any FDA decision, Marks said.

Earlier this year, the FDA gave emergency authorization for hospitals to use malaria drug hydroxychloroquine as a Covid-19 treatment after it had been touted by Trump. The agency later withdrew the authorization after data showed hydroxychloroquine was of no benefit and could harm some patients.

Hahn, Marks and another FDA official penned an article in the Journal of the American Medical Association this month acknowledging public anxiety about lowering regulatory standards to approve a coronavirus vaccine.

"FDA is committed to ensuring that any vaccine is manufactured in accordance with all of FDA's quality standards and that its safety and effectiveness are verified before being authorized or licensed," they wrote.

The officials also pledged that the FDA's vaccine advisory committee would conduct a "transparent discussion" in advance of any vaccine authorization or license.

It is unclear whether any of the vaccine trials will enroll enough subjects and yield meaningful data for the FDA to review ahead of the US election.

AstraZeneca could supply the first doses of its vaccine to the United States as soon as October, "assuming FDA approval of safety and efficacy or emergency use authorization of the vaccine," a company spokesman said in a statement to Reuters. He declined to address whether AstraZeneca would have sufficient data to submit to the FDA by then.

"It is important to remember that — while the data so far is certainly encouraging — there is no guarantee that this vaccine will ultimately be approved or granted an emergency use authorization," the spokesman said.

Pfizer said in a statement that it expects to file with the FDA for emergency authorization or "some form of regulatory approval" as early as October. Moderna did not immediately respond to a request for comment.

Kathryn Edwards, former chairwoman of the FDA's vaccine advisory committee and scientific director at the Vanderbilt Vaccine Research Program, said she does not believe the group would allow itself to be strong-armed into recommending a candidate if the data is inadequate. "If it is not done right, there will be such a hue and cry from the scientific community that it will be clearly heard," she said.

FDA

Comments

While most comments will be posted if they are on-topic and not abusive, moderation decisions are subjective. Published comments are readers’ own views and The Business Standard does not endorse any of the readers’ comments.

Top Stories

  • A man stands in front of collapsed buildings following an earthquake in Kahramanmaras, Turkey February 6, 2023. Ihlas News Agency (IHA) via REUTERS ATTENTION EDITORS - THIS PICTURE WAS PROVIDED BY A THIRD PARTY. NO RESALES. NO ARCHIVES. TURKEY OUT. NO COMMERCIAL OR EDITORIAL SALES IN TURKEY.
    Deaths exceed 2,600 as catastrophic quakes ravage Turkey, Syria
  • 30% cos see double-digit growth even in hard times
    30% cos see double-digit growth even in hard times
  • Govt borrowing from commercial banks surges
    Govt borrowing from commercial banks surges

MOST VIEWED

  • A black smoke from a fire is seen at the Iskenderun port after an earthquake in Iskenderun, Turkey February 6, 2023. REUTERS/Ece Toksabay
    Large fire, plume of smoke at Turkey's Iskenderun port
  • A civil defence vehicle is seen near rubble, following an earthquake, in Aleppo, Syria, in this handout released by SANA on February 6, 2023. SANA/Handout via REUTERS
    Russia says 300 army personnel clearing debris in Syria
  • People wait their turn to get fuel at a petrol station, in Karachi, Pakistan June 2, 2022. Picture taken June 2, 2022. REUTERS/Akhtar Soomro/File Photo
    Pakistan, IMF grapple for consensus to unlock critical funding
  • File photo. Somalia soldiers and policemen look on as Hassan Hanafi, a former media officer for the Somali Islamist group al Shabaab, stands tied to a pole before his execution by shooting at close range on a field in General Kahiye Police Academy in Somalia's capital Mogadishu, on April 11, 2016. REUTERS/Ismail Taxta
    At least 34 killed in clashes in Somaliland - two doctors at public hospital
  • Syria hospital treating earthquake victims pleads for help
    Syria hospital treating earthquake victims pleads for help
  • How should you talk to ChatGPT? A user's guide
    How should you talk to ChatGPT? A user's guide

Related News

  • US FDA approves Mirati's lung cancer drug
  • California lab-grown meat start-up gets first green light
  • US FDA authorizes Eli Lilly's Covid-19 antibody drug
  • Pfizer asks FDA to allow Covid-19 vaccine for kids under 5
  • FDA expands use of remdesivir to patients with high risk of hospitalization

Features

Photo: Collected

Get your partner a lovely present this Valentine's Day

21h | Brands
Pottery Wheel Craft Kit: A creative outlet for little hands

Pottery Wheel Craft Kit: A creative outlet for little hands

20h | Brands
Say it with Colours

Say it with Colours

1d | Mode
Photo: Courtesy

From 'Made in Bangladesh' to 'Designed in Bangladesh'

1d | Panorama

More Videos from TBS

Who will survive? Adani or Hindenburg?

Who will survive? Adani or Hindenburg?

11h | TBS Stories
James Gunn’s 8-10-year plan for the DC Universe

James Gunn’s 8-10-year plan for the DC Universe

11h | TBS Entertainment
LC issues lead to severe shortage of surgical equipment

LC issues lead to severe shortage of surgical equipment

14h | TBS Insight
Stage plays are going on in the digital age

Stage plays are going on in the digital age

19h | TBS Stories

Most Read

1
Leepu realised his love for cars from a young age and for the last 40 years, he has transformed, designed and customised hundreds of cars. Photo: Collected
Panorama

'I am not crazy about cars anymore': Nizamuddin Awlia Leepu

2
The International Monetary Fund (IMF) logo is seen outside the headquarters building in Washington, U.S., September 4, 2018. REUTERS/Yuri Gripas/File Photo
Economy

IMF approves $4.7 billion loan for Bangladesh, calls for ambitious reforms

3
Belal Ahmed new acting chairman of SIBL
Banking

Belal Ahmed new acting chairman of SIBL

4
Fund cut as Dhaka's fast-track transit projects on slow spending lane
Infrastructure

Fund cut as Dhaka's fast-track transit projects on slow spending lane

5
Photo: Collected
Startups

ShopUp secures $30m debt financing to boost expansion, supply chain

6
Photo: Courtesy
Panorama

From 'Made in Bangladesh' to 'Designed in Bangladesh'

EMAIL US
[email protected]
FOLLOW US
WHATSAPP
+880 1847416158
The Business Standard
  • About Us
  • Contact us
  • Sitemap
  • Privacy Policy
  • Comment Policy
Copyright © 2023
The Business Standard All rights reserved
Technical Partner: RSI Lab

Contact Us

The Business Standard

Main Office -4/A, Eskaton Garden, Dhaka- 1000

Phone: +8801847 416158 - 59

Send Opinion articles to - [email protected]

For advertisement- [email protected]